Kite Pharma

Kite Pharma does not manage external investment capital; it is a wholly owned clinical-stage and commercial biotherapeutics subsidiary of Gilead Sciences. Strategic and capital-allocation decisions — including the 2017 acquisition and subsequent bolt-on deals like Arcellx — are made by Gilead's executive leadership and board. The Kite unit is not a family office or fund and does not allocate to outside managers.

Kite Pharma is neither. It is a cell-therapy-focused research, development, and manufacturing organization that functions as a division of Gilead Sciences. It does not invest in startups or external funds; instead it deploys capital into its own clinical programs, manufacturing capacity, and complementary acquisitions that can be integrated into its oncology pipeline.

Kite Pharma does not manage third-party assets and does not report an AUM figure. As a consolidated subsidiary of Gilead, its R&D and commercial expenditures are funded through the parent's corporate balance sheet. Gilead's oncology segment, which encompasses Kite, reported $2.2 billion in revenue for full-year 2025 (per Gilead annual filing, 2026).

Kite is not a fund investor. It acquires companies — such as the $2.5 billion Arcellx deal announced in February 2026 — and in-licenses technology platforms at late preclinical or early clinical stages to feed its pipeline. The unit does not make venture-stage minority investments as a core activity.

Kite Pharma has been a wholly owned subsidiary of Gilead Sciences since the acquisition closed in October 2017 for roughly $11.9 billion in cash. Gilead maintains Kite as a distinct brand and operational unit within its oncology segment, and Kite's clinical, regulatory, and manufacturing activities are reported through Gilead's consolidated financials.